StockData
BridgeBio Oncology Therapeutics, Inc. logo

BridgeBio Oncology Therapeutics, Inc. (BBOT) stock

BBOTNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 6/30
$1.94−0.04 (-2.02%)

Close on Nov 17, 2026Market cap $155.54MP/E –Yield –

BridgeBio Oncology Therapeutics operating cash flow

Operating cash flow is the cash the business generates from its day-to-day operations.

BridgeBio Oncology Therapeutics's operating cash flow for the twelve months ending Jun 30, 2026 was -$151.28M. For fiscal 2025 it was -$113.89M.

Annual operating cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$113.89M–
FY2024Dec 31, 2024-$55.03M–

Quarterly operating cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$44.36M–
Q1 FY2026Mar 31, 2026-$35.92M–
Q4 FY2025Dec 31, 2025-$42.23M–
Q3 FY2025Sep 30, 2025-$28.77M–
Q2 FY2025Jun 30, 2025-$23.29M–
Q1 FY2025Mar 31, 2025-$19.60M–
Q4 FY2024Dec 31, 2024-$15.04M–
Q3 FY2024Sep 30, 2024-$39.34M–
Q2 FY2024Jun 30, 2024-$29.10K–
Q1 FY2024Mar 31, 2024-$618.00K–

More BridgeBio Oncology Therapeutics figures

See a number that looks wrong?